Shopping Cart

Your shopping cart is currently empty

Primaquine diphosphate

Name: Primaquine diphosphate
Brand: TargetMol
SKU: T0850
Price: 29 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T0850Cas No. 63-45-6

Alias Primaquine phosphate, Primaquine bisphosphate

Primaquine diphosphate is the phosphate salt form of primaquine, a synthetic, 8-aminoquinoline derivative with antimalarial properties. Although its mechanism of action is unclear, primaquine bind to and alter the properties of protozoal DNA. This agent eliminates tissue (exo-erythrocytic) malarial infection, preventing the development of the erythrocytic forms of the parasite which are responsible for relapses in Plasmodium vivax and ovale malaria. Primaquine is active against late hepatic stages (hypnozoites, schizonts).

Primaquine diphosphate

Copy Product Info

😃Good

Purity: 99.82%

Catalog No. T0850Alias Primaquine phosphate, Primaquine bisphosphateCas No. 63-45-6

Pack Size	Price	USA Warehouse	Global Warehouse
1 g	$40	-	In Stock
2 g	$51	-	In Stock
1 mL x 10 mM (in DMSO)	$29	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.82%

Color:Orange to Red

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity

Description	Primaquine diphosphate is the phosphate salt form of primaquine, a synthetic, 8-aminoquinoline derivative with antimalarial properties. Although its mechanism of action is unclear, primaquine bind to and alter the properties of protozoal DNA. This agent eliminates tissue (exo-erythrocytic) malarial infection, preventing the development of the erythrocytic forms of the parasite which are responsible for relapses in Plasmodium vivax and ovale malaria. Primaquine is active against late hepatic stages (hypnozoites, schizonts).
In vivo	Primaquine effectively counters all exoerythrocytic forms of parasites and is used in conjunction with other antimalarial drugs to treat vivax and ovale malaria. It remains an efficacious malaria-blocking agent, exhibiting notable activity against the gametocytes of all human malaria, including multidrug-resistant strains of P. falciparum. The specific mechanism by which Primaquine eliminates P. falciparum and gametocytes is unclear, but studies suggest it involves disruptions to the parasite's mitochondrial metabolism, impairing coenzyme Q's role as an electron carrier in the respiratory chain, and potential generation of highly reactive metabolites leading to increased oxidative potential. Primaquine can block calcium-release-activated channels in rat megakaryocytes and may also act as an inhibitor of vesicular transport. It inhibits protein transport (IC50: 50 μM) and vesicle budding in donor cell membranes. Primaquine significantly suppresses the recycling of phagocytosed proteins to the plasma membrane and inhibits potassium channel currents by blocking muscarinic acetylcholine receptors. It also inhibits human erythrocyte membrane acetylcholinesterase (IC33: 30 μM) and affects the sodium channels in isolated rat ventricular muscle and myocytes.
Synonyms	Primaquine phosphate, Primaquine bisphosphate

Chemical Properties

Molecular Weight	455.34
Formula	C₁₅H₂₁N₃O·2H₃PO₄
Cas No.	63-45-6
Smiles	CC(CCCN)Nc1c2c(cc(c1)OC)cccn2.OP(=O)(O)O.OP(=O)(O)O
Relative Density.	no data available

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 245 mg/mL (538.06 mM), Sonication is recommended.

Ethanol: < 1 mg/mL (insoluble or slightly soluble)

H2O: 83 mg/mL (182.28 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.39 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

H2O/DMSO

	1mg	5mg	10mg	50mg
1 mM	2.1962 mL	10.9808 mL	21.9616 mL	109.8081 mL
5 mM	0.4392 mL	2.1962 mL	4.3923 mL	21.9616 mL
10 mM	0.2196 mL	1.0981 mL	2.1962 mL	10.9808 mL
20 mM	0.1098 mL	0.5490 mL	1.0981 mL	5.4904 mL
50 mM	0.0439 mL	0.2196 mL	0.4392 mL	2.1962 mL
100 mM	0.0220 mL	0.1098 mL	0.2196 mL	1.0981 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc